In this context, the administration of metformin, an insulin-sensitizing drug known to impact the gut microbiota and contribute to increased levels of Bifidobacterium and Akkermansia, has been recently associated with a decreased incidence of HCC via regulating the FXR signaling pathway, ultimately sustaining anti-inflammatory effects [136]. This evidence concerns the gene NR1H4 and hepatocellular carcinoma.